Physician profile
Robert B Young
NPI 1033179908
$7,905.43
in general payments reported to CMS, 2019-2025
9 companies · $38.57 in 2025
The $38.57 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $145 · 2024: $7,722 · 2025: $38.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,150 · Travel and Lodging: $504 · Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,150.00 |
| Travel and Lodging | $504.17 |
| Food and Beverage | $251.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $7,654.17 | 2024 | |
| Neurocrine Biosciences, INC. | $51.14 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $44.96 | 2024 | Invega Sustenna |
| Alkermes, INC. | $39.47 | 2023 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $34.31 | 2023 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $23.39 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.90 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $19.42 | 2023 | Austedo |
| Braeburn INC. | $16.67 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.